세계의 루푸스 치료제 시장

Global Lupus Therapeutics Market to Reach US$7.5 Billion by 2030

The global market for Lupus Therapeutics estimated at US$4.2 Billion in the year 2023, is expected to reach US$7.5 Billion by 2030, growing at a CAGR of 8.6% over the analysis period 2023-2030. Anti-Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 8.2% CAGR

The Lupus Therapeutics market in the U.S. is estimated at US$1.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.9% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.

Global Lupus Therapeutics Market - Key Trends & Drivers Summarized

What Challenges and Opportunities Exist in Lupus Treatment Today?

Lupus, a chronic autoimmune disease characterized by the immune system attacking its own tissues, presents significant treatment challenges due to its complex and varied symptoms, ranging from mild skin rashes to severe kidney damage. Traditional lupus therapies have largely revolved around non-specific immunosuppressants, such as corticosteroids and antimalarial drugs, which can have wide-ranging side effects and vary in effectiveness. However, the growing understanding of the disease's underlying biological pathways has opened up opportunities for targeted therapies, which aim to modulate specific immune system components without broad immunosuppression. These advancements represent a shift towards more personalized medicine in lupus treatment, focusing on patient-specific disease manifestations and genetic profiles, improving both treatment efficacy and quality of life for patients.

How Are New Technologies Revolutionizing Lupus Treatment?

The integration of biotechnology and pharmacological advancements has begun to revolutionize lupus treatment. The development of biologic drugs, specifically designed to target particular immune system molecules, has provided new hope for patients who do not respond to conventional therapies. For instance, monoclonal antibodies that inhibit immune system proteins, which are pivotal in the development of inflammation, have shown promise in reducing the severity of lupus symptoms. Additionally, advancements in genomics have facilitated the identification of genetic markers associated with the disease, potentially leading to earlier diagnosis and more tailored treatment strategies. These technological innovations not only enhance the precision of lupus therapies but also help in reducing the occurrence of severe side effects that are often associated with traditional treatment options.

What Impact Does Patient Advocacy and Awareness Have on the Lupus Therapeutics Market?

Increased awareness and patient advocacy are playing critical roles in transforming the lupus therapeutics market. Enhanced public and medical understanding of lupus, driven by patient advocacy groups, has led to earlier diagnosis and treatment interventions, which are crucial in managing the disease effectively. These groups have also been instrumental in pushing for more research funding and better healthcare policies that support the development and accessibility of new therapies. Additionally, the global rise in health literacy has empowered patients to actively participate in their treatment decisions, increasing demand for newer, less toxic, and more effective medications. This shift towards patient-centered care in the lupus therapeutics market is not only improving outcomes but is also influencing drug development priorities and healthcare practices.

Growth in the Lupus Therapeutics Market Is Driven by Several Factors

The growth in the lupus therapeutics market is driven by several factors, including advances in medical research that enhance understanding of the disease, developments in genetic testing, and the introduction of novel medications. Increased investment in research and development has led to the emergence of new drugs that target specific pathways involved in the immune response, offering alternatives to traditional treatments with fewer side effects. Furthermore, regulatory support for drug development, such as the FDA’s fast track and breakthrough therapy designations, accelerates the approval process for promising lupus treatments, enhancing their commercial viability and market entry. The growing patient advocacy for better healthcare solutions also stimulates demand for innovative treatments, ensuring continued investment and interest in this field. Together, these dynamics underscore a market geared towards extensive growth and transformation, promising a new era of options for lupus management.

Select Competitors (Total 17 Featured) -

• Bayer AG, Pharmaceuticals
• Better Therapeutics
• Biogen, Inc.
• Biomix Network Ltd.
• Bristol-Myers Squibb Company
• Equillium
• Merck KGaA
• The NIAID Vaccine Research Center
• The Peter Doherty Institute for Infection and Immunity

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Lupus Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Lupus Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Lupus Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Lupus Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Immunosuppressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Immunosuppressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Immunosuppressant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Antimalarial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Antimalarial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Antimalarial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for BLyS-Specific Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for BLyS-Specific Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for BLyS-Specific Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Biologicals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Biologicals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 21: World 16-Year Perspective for Biologicals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 24: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 25: World Lupus Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
• JAPAN
  • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 32: Japan Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Japan Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Japan 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
• CHINA
  • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 35: China Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: China Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: China 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
• EUROPE
  • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 38: Europe Recent Past, Current & Future Analysis for Lupus Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 39: Europe Historic Review for Lupus Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Europe 16-Year Perspective for Lupus Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 41: Europe Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Europe Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Europe 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
• FRANCE
  • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 44: France Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: France Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: France 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
• GERMANY
  • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 47: Germany Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Germany Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Germany 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 50: Italy Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Italy Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Italy 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 53: UK Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: UK Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: UK 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Rest of Europe Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Rest of Europe 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Asia-Pacific Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Asia-Pacific 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Rest of World Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Rest of World 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION